- Home
- LFCR vs RLMD Comparison
LFCR vs RLMD Comparison
Compare LFCR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | RLMD |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.8M | 319.7M |
| IPO Year | 1996 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LFCR | RLMD |
|---|---|---|
| Price | $4.15 | $6.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.50 | ★ $10.25 |
| AVG Volume (30 Days) | 279.4K | ★ 1.5M |
| Earning Date | 03-16-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $557,559,000.00 | $13,070.00 |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.36 | ★ 154.83 |
| 52 Week Low | $4.09 | $0.24 |
| 52 Week High | $8.98 | $7.41 |
Technical Indicators
Market Signals| Indicator | LFCR | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 9.73 | 61.82 |
| Support Level | N/A | $3.74 |
| Resistance Level | $8.54 | $7.41 |
| Average True Range (ATR) | 0.50 | 0.49 |
| MACD | -0.30 | 0.10 |
| Stochastic Oscillator | 0.92 | 63.21 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.